CJC-1295 NO DAC 5 mg
research-grade
lyophilized peptide powder
supplied in a glass vial. CJC-1295 NO DAC, also known as
Modified GRF (1-29) or
Mod GRF 1-29,
is a synthetic peptide analog of Growth Hormone-Releasing Hormone (GHRH) studied in experimental models of pituitary growth hormone release,
GHRH receptor agonism and pulsatile GH secretion.
Research Use Only:
All products are intended exclusively for laboratory and scientific research. Not for human or veterinary use.
Purity
High-purity research grade
Form
Lyophilized peptide powder
Content
5 mg CJC-1295 NO DAC per vial
Packaging
Glass vial with sterile closure
Storage
Store lyophilized at 2–8 °C (desiccated, protect from light)
Molecular formula
C152H252N44O42
Molecular weight
~3367.9 g·mol⁻¹
Sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
In laboratory workflows, lyophilized research peptides are typically handled with suitable sterile diluents such as bacteriostatic water (BAC).
For a compatible research-only solvent, see
Bacteriostatic water – 10 ml
.
Research Overview
CJC-1295 NO DAC (Modified GRF 1-29) is a synthetic analog of Growth Hormone-Releasing Hormone composed of the first 29 amino acids of native
GHRH with selected substitutions to enhance stability and receptor affinity. In experimental in vitro and in vivo models it is used to
investigate pituitary growth hormone release, GHRH receptor activation and short-lived, pulsatile GH secretion patterns under controlled
conditions.
Primary Research Areas
-
GHRH receptor agonism:
used to study selective activation of the Growth Hormone-Releasing Hormone receptor and downstream cAMP/PKA signaling in pituitary and
related cellular models.
-
Growth hormone (GH) release:
applied in experimental systems evaluating GH pulse amplitude and frequency, pituitary responsiveness and feedback regulation of the
somatotropic axis.
-
Pulsatile secretion patterns:
investigated for its short half-life profile and use in models designed to mimic physiological, pulsatile GH release rather than continuous
exposure paradigms.
-
Pituitary function assessment:
included in research protocols probing pituitary reserve, GH–IGF-1 axis integrity and interactions with other hypothalamic–pituitary hormones
in animals and ex vivo tissues.
-
Combination with GHRPs/GHSs:
used in combination studies with growth hormone secretagogues (GHRPs/GHSs) to explore potential synergistic or additive effects on GH release
and downstream signaling endpoints in laboratory models.
